# PYXS — Pyxis Oncology Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** PYXS  
**Sources:** 19  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-pyxs-pyxis-oncology-inc-catalysts-narrative-risks-10399

---

# Pyxis Oncology, Inc. (PYXS) — As of October 31, 2026

*Not investment advice.*

## Company Snapshot
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a Boston-based, clinical-stage biopharmaceutical company (founded 2019, listed on Nasdaq in 2021) developing next-generation therapeutics for difficult-to-treat solid tumors via antibody-drug conjugate (ADC) and immuno-oncology platforms. Its lead candidate is **micvotabart pelidotin (MICVO)**, formerly PYX-201, an ADC that targets extradomain-B of fibronectin (EDB+FN). [[10]](https://www.marketbeat.com/earnings/reports/2026-11-2-pyxis-oncology-inc-stock/), [[20]](https://pyxisoncology.com/)

As of the October 30, 2026 close, PYXS traded at ~$1.81 with a market capitalization of ~$225.8M. [[16]](https://tickernerd.com/stock/pyxs-forecast/), [[17]](https://stockanalysis.com/stocks/pyxs/forecast/) The stock has been highly volatile: down ~22.3% over the past month and ~47.1% over the trailing year, while sitting well below its 52-week high of $5.55. [[16]](https://tickernerd.com/stock/pyxs-forecast/)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-pyxs-pyxis-oncology-inc-catalysts-narrative-risks-10399 (free to sign up)._